India Vaccine Maker Is Still Testing AstraZeneca’s Shot After Firm Halts Trials
The Indian company enlisted to manufacture a billion doses ofAstraZeneca Plc’s experimental Covid-19 vaccine is pushing ahead with its own clinical trial even as safety concerns forced the British drugmaker to halt its tests.
TheSerum Institute of India said it received a notice from the Drug Controller General of India seeking information on the illness of a person participating in AstraZeneca’s trials in Britain. The regulator asked Serum to demonstrate why its clinical trial license should not be suspended until the safety of the vaccine is established, according to areport from the Press Trust of India.
Serum said it was responding to the regulator’s queries, but was proceeding with its own human trials in India in the meantime.
“The Indian trials are continuing and we have faced no issues at all,” Serum said in a statement on its official Twitter account. “We were going by DCGI’s direction and were not instructed to pause the trials. If DCGI has any safety concerns, we will adhere to their instructions and abide by the standard protocols.”
95,735 in IndiaMost new cases today
-1% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-1.047 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
5.3% Global GDP Tracker (annualized), Aug.